Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Vertex Expands Gene-Editing Efforts With A Pair Of Deals

Executive Summary

CF-focused Vertex will buy Exonics and expand a collaboration with CRISPR Therapeutics, with plans to develop therapies for DMD and myotonic dystrophy type 1. Merck acquires TGFβ-focused Tilos, while Achaogen offloads most of its assets at auction.

Advertisement

Related Content

BIO 2019 Notebook: M&A Soars, Lartruvo Lookback, BIO Vs. ASCO
Spotlight on Q1 Pharma M&A Merry-Go-Round
Bayer Pays Arvinas $50m To Form Protein Degrader R&D Pact
Time For AI To Deliver In Drug Discovery, Says Atomwise CEO
BIO 2019 Notebook: Merck; Out-Licensing Deals; RMAT
BI Inks Second Obesity Pact With Denmark’s Gubra
Vertex Selects VX-445 For CF Triple Therapy Due To Safety/Tolerability
Santhera Shores Up Finances With Chiesi Deal for Raxone
Finance Watch: Turning Point Launches IPO, Stock Rises 60% On First Day
Vical Faced With Failure of Another Vaccine Trial

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC125368

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel